SPONSORS

SUPPORTING SPONSOR

Genentech

Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.

INNOVATION SPONSORS

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E ™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901, is an investigational sustained delivery.

Neurotech Pharmaceuticals

Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies to slow the progression of Macular Telangiectasia (MacTel) Type 2 and other chronic retinal diseases through its core platform technology, Encapsulated Cell Therapy (ECT). To learn more, visit https://www.neurotechpharmaceuticals.com/.

Oculis

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline includes: OCS-01, a topical candidate in Phase 3 for diabetic macular edema and inflammation and pain following ocular surgery; OCS-02, a topical biologic candidate in Phase 2b for dry eye disease and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophthalmic disorders. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team and supported by leading international healthcare investors.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD. ONL1204, the Company's lead compound, is currently being used in three Phase 1b studies in the indications of retinal detachment, Geographic Atrophy and Open Angle Glaucoma. The Company is preparing to enter Phase 2 studies in the same indications.